

June 13, 2011
AnGes MG, Inc.

Medical-Use Patent for GEN0101/TSD-0014 (HVJ-E) Granted in Japan
- Intended for Anti-Cancer Drugs -

AnGes MG, Inc. and its subsidiary, GenomIdea, Inc. are pleased to announce that the medical use-patent for GEN0101/TSD-0014 (HVJ-E) intended for cancer treatment was granted in Japan. (Patent No.4746877)

The substance patent for GEN0101/TSD-0014 (HVJ-E) was already granted (Patent No. 3942362), and has been licensed to Ishihara Sangyo Kaisha, Ltd. (hereinafter called “Ishihara Sangyo”) for use as reagents for research. Ishihara Sangyo launched GenomONE[®] Series (reagents for gene and protein transfection) and GenomONE[®]-CF (reagents for cell fusion). Also in the U.S., Cosmo Bio Co., Ltd. launched GenomONE[®]-Neo EX HVJ Envelope Transfection Kit and GenomONE[®]-CF EX HVJ Envelope Cell Fusion Kit.

On the other hand, the present patent was newly applied for because it was newly discovered that GEN0101/TSD-0014 (HVJ-E) has an independent immunostimulatory action besides its gene delivery vector function.

More specifically, it is intended that various kinds of solid cancers will be treated by local administration of GEN0101/TSD-0014 (HVJ-E) to the site of cancer. Characteristically, this method involves very few serious adverse reactions unlike chemotherapeutic agents and radiotherapies which are the mainstream cancer treatments today, and also the method may be effective for cancers for which there have been few effective drugs so far, such as prostate cancer and skin cancers.

Currently, a team at Osaka University is conducting clinical research for melanoma (malignant melanoma), a type of skin cancer. There are expectations for the application of GEN0101/TSD-0014 (HVJ-E) in the area of pharmaceuticals.

In GEN0101/TSD-0014 (HVJ-E), the viral genome is inactivated, and therefore it has a characteristically high level of safety unlike conventional viral vectors. There are expectations that HVJ-E will be able to be used as completely new types of anti-cancer drugs as well.

This patent is valid until October 2023. It is also protected in the U.S. as US7871765 until March 2025, and is currently pending in Europe.

AnGes MG group aims to expand the application of GEN0101/TSD-0014 (HVJ-E) to many other solid cancers, by taking advantage of its characteristics and its long-term patent protection.

Meanwhile, this trend will have no effect on AnGes MG’s business performance for the current fiscal year.